
Acorda Therapeutics (ACOR) Stock Forecast & Price Target
Acorda Therapeutics (ACOR) Analyst Ratings
Based on 13 analyst ratings
Hold
Strong Buy 31%
Buy 8%
Hold 54%
Sell 0%
Strong Sell 8%
Acorda Therapeutics (ACOR) has been analyzed by 13 analysts, with a consensus rating of Hold. 31% of analysts recommend a Strong Buy, 8% recommend Buy, 54% suggest Holding, 0% advise Selling, and 8% predict a Strong Sell.
This aggregate rating is based on analysts' research of Acorda Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
This aggregate rating is based on analysts' research of Acorda Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Acorda Therapeutics (ACOR) Analyst Forecast & Price Prediction
Get the latest Acorda Therapeutics (ACOR) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis
Start investing in Acorda Therapeutics (ACOR)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Acorda Therapeutics (ACOR) Forecast
Analysts have given Acorda Therapeutics (ACOR) a Hold based on their latest research and market trends.
According to 13 analysts, Acorda Therapeutics (ACOR) has a Hold consensus rating as of Jul 29, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.
Wall Street analysts have set a price target of $30.62, reflecting a 0.00% increase from the current stock price.
Financial analysts have set a price target of $30.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.